Fig. 6.
MR signal enhancement up to 8-week post-treatment with targeted fumagillin nanoparticles and/or oral atorvastatin. Top: Untreated and statin treated animals showed a constant level of angiogenesis in the aortic wall. Animals treated with targeted fumagillin nanoparticles at weeks 0 and 4 showed decreased angiogenesis (* P < 0.05) following each dose, which returned to baseline levels within 4 weeks. Bottom: The combination of two fumagillin doses and statin produced a sustained decrease in angiogenesis (* P < 0.05). Green arrow points to synergistic suppression of angiogenesis not achieved with statin or fumagillin alone (see top panel). Reproduced with permission [64]